Pharma & Healthcare
Global Drugs for Spinal Muscular Atrophy (SMA) Market Research Report 2026
- Feb 24, 26
- ID: 720716
- Pages: 101
- Figures: 96
- Views: 1
This report delivers a comprehensive overview of the global Drugs for Spinal Muscular Atrophy (SMA) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Drugs for Spinal Muscular Atrophy (SMA). The Drugs for Spinal Muscular Atrophy (SMA) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Drugs for Spinal Muscular Atrophy (SMA) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Drugs for Spinal Muscular Atrophy (SMA) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novartis
Genentech
Biogen
Ionis Pharmaceuticals
Segment by Type
Oral Drugs
Injections
by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Drugs for Spinal Muscular Atrophy (SMA) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Drugs for Spinal Muscular Atrophy (SMA) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Drugs for Spinal Muscular Atrophy (SMA) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Drugs for Spinal Muscular Atrophy (SMA) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novartis
Genentech
Biogen
Ionis Pharmaceuticals
Segment by Type
Oral Drugs
Injections
by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Drugs for Spinal Muscular Atrophy (SMA) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Drugs for Spinal Muscular Atrophy (SMA) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Drugs for Spinal Muscular Atrophy (SMA) Market Overview
1.1 Product Definition
1.2 Drugs for Spinal Muscular Atrophy (SMA) by Type
1.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type: 2025 vs 2032
1.2.2 Oral Drugs
1.2.3 Injections
1.3 Drugs for Spinal Muscular Atrophy (SMA) by Application
1.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Estimates and Forecasts
1.4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue 2021–2032
1.4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales 2021–2032
1.4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Drugs for Spinal Muscular Atrophy (SMA) Market Competition by Manufacturers
2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Drugs for Spinal Muscular Atrophy (SMA), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Types and Applications
2.7 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Date of Entry into the Industry
2.8 Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation and Trends
2.8.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue
2.8.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Scenario by Region
3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021–2032
3.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021–2026
3.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2027–2032
3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021–2032
3.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021–2026
3.3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2027–2032
3.4 North America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.4.1 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.4.3 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.5.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.5.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021–2032)
3.6.3 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.7.1 Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.7.3 Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021–2032)
4.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021–2026)
4.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027–2032)
4.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021–2032)
4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021–2032)
4.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021–2026)
4.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027–2032)
4.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021–2032)
4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021–2032)
5.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021–2026)
5.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027–2032)
5.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021–2032)
5.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021–2032)
5.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021–2026)
5.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027–2032)
5.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021–2032)
5.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Genentech
6.2.1 Genentech Company Information
6.2.2 Genentech Description and Business Overview
6.2.3 Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.2.5 Genentech Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Company Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Ionis Pharmaceuticals
6.4.1 Ionis Pharmaceuticals Company Information
6.4.2 Ionis Pharmaceuticals Description and Business Overview
6.4.3 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.4.5 Ionis Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Chain Analysis
7.2 Drugs for Spinal Muscular Atrophy (SMA) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process Analysis
7.4 Drugs for Spinal Muscular Atrophy (SMA) Sales and Marketing
7.4.1 Drugs for Spinal Muscular Atrophy (SMA) Sales Channels
7.4.2 Drugs for Spinal Muscular Atrophy (SMA) Distributors
7.5 Drugs for Spinal Muscular Atrophy (SMA) Customer Analysis
8 Drugs for Spinal Muscular Atrophy (SMA) Market Dynamics
8.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Trends
8.2 Drugs for Spinal Muscular Atrophy (SMA) Market Drivers
8.3 Drugs for Spinal Muscular Atrophy (SMA) Market Challenges
8.4 Drugs for Spinal Muscular Atrophy (SMA) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Drugs for Spinal Muscular Atrophy (SMA) by Type
1.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type: 2025 vs 2032
1.2.2 Oral Drugs
1.2.3 Injections
1.3 Drugs for Spinal Muscular Atrophy (SMA) by Application
1.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Estimates and Forecasts
1.4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue 2021–2032
1.4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales 2021–2032
1.4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Drugs for Spinal Muscular Atrophy (SMA) Market Competition by Manufacturers
2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Drugs for Spinal Muscular Atrophy (SMA), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Types and Applications
2.7 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Date of Entry into the Industry
2.8 Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation and Trends
2.8.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue
2.8.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Scenario by Region
3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021–2032
3.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2021–2026
3.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2027–2032
3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021–2032
3.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021–2026
3.3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2027–2032
3.4 North America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.4.1 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.4.3 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.5.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.5.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2021–2032)
3.6.3 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.7.1 Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.7.3 Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021–2032)
4.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2021–2026)
4.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2027–2032)
4.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021–2032)
4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021–2032)
4.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2021–2026)
4.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2027–2032)
4.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021–2032)
4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021–2032)
5.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2021–2026)
5.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2027–2032)
5.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021–2032)
5.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021–2032)
5.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2021–2026)
5.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2027–2032)
5.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021–2032)
5.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Genentech
6.2.1 Genentech Company Information
6.2.2 Genentech Description and Business Overview
6.2.3 Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.2.5 Genentech Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Company Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Ionis Pharmaceuticals
6.4.1 Ionis Pharmaceuticals Company Information
6.4.2 Ionis Pharmaceuticals Description and Business Overview
6.4.3 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.4.5 Ionis Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Chain Analysis
7.2 Drugs for Spinal Muscular Atrophy (SMA) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process Analysis
7.4 Drugs for Spinal Muscular Atrophy (SMA) Sales and Marketing
7.4.1 Drugs for Spinal Muscular Atrophy (SMA) Sales Channels
7.4.2 Drugs for Spinal Muscular Atrophy (SMA) Distributors
7.5 Drugs for Spinal Muscular Atrophy (SMA) Customer Analysis
8 Drugs for Spinal Muscular Atrophy (SMA) Market Dynamics
8.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Trends
8.2 Drugs for Spinal Muscular Atrophy (SMA) Market Drivers
8.3 Drugs for Spinal Muscular Atrophy (SMA) Market Challenges
8.4 Drugs for Spinal Muscular Atrophy (SMA) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation by Manufacturers in 2025
Table 4. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Drugs for Spinal Muscular Atrophy (SMA), Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Types and Applications
Table 12. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Drugs for Spinal Muscular Atrophy (SMA) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Drugs for Spinal Muscular Atrophy (SMA) Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2021–2026
Table 18. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021–2026)
Table 19. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2027–2032
Table 20. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2027–2032)
Table 21. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2021–2026
Table 22. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021–2026)
Table 23. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2027–2032
Table 24. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2027–2032)
Table 25. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
Table 27. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
Table 28. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
Table 29. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
Table 32. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
Table 33. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
Table 42. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
Table 43. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
Table 50. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Type (2021–2026)
Table 51. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Type (2027–2032)
Table 52. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021–2026)
Table 53. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2027–2032)
Table 54. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021–2026)
Table 57. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2027–2032)
Table 58. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2021–2026)
Table 59. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2027–2032)
Table 60. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Application (2021–2026)
Table 61. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Application (2027–2032)
Table 62. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021–2026)
Table 63. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2027–2032)
Table 64. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021–2026)
Table 67. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2027–2032)
Table 68. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2021–2026)
Table 69. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2027–2032)
Table 70. Novartis Company Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Novartis Drugs for Spinal Muscular Atrophy (SMA) Product
Table 74. Novartis Recent Developments/Updates
Table 75. Genentech Company Information
Table 76. Genentech Description and Business Overview
Table 77. Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Genentech Drugs for Spinal Muscular Atrophy (SMA) Product
Table 79. Genentech Recent Developments/Updates
Table 80. Biogen Company Information
Table 81. Biogen Description and Business Overview
Table 82. Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Biogen Drugs for Spinal Muscular Atrophy (SMA) Product
Table 84. Biogen Recent Developments/Updates
Table 85. Ionis Pharmaceuticals Company Information
Table 86. Ionis Pharmaceuticals Description and Business Overview
Table 87. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product
Table 89. Ionis Pharmaceuticals Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Drugs for Spinal Muscular Atrophy (SMA) Distributors List
Table 93. Drugs for Spinal Muscular Atrophy (SMA) Customers List
Table 94. Drugs for Spinal Muscular Atrophy (SMA) Market Trends
Table 95. Drugs for Spinal Muscular Atrophy (SMA) Market Drivers
Table 96. Drugs for Spinal Muscular Atrophy (SMA) Market Challenges
Table 97. Drugs for Spinal Muscular Atrophy (SMA) Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Product Picture of Drugs for Spinal Muscular Atrophy (SMA)
Figure 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Type: 2025 & 2032
Figure 4. Oral Drugs Product Picture
Figure 5. Injections Product Picture
Figure 6. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Application: 2025 & 2032
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Other
Figure 11. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (US$ Million), 2021–2032
Figure 13. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), 2021–2032
Figure 14. Global Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit), 2021–2032
Figure 15. Drugs for Spinal Muscular Atrophy (SMA) Report Years Considered
Figure 16. Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Manufacturers in 2025
Figure 17. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Drugs for Spinal Muscular Atrophy (SMA) Players: Market Share by Revenue in Drugs for Spinal Muscular Atrophy (SMA) in 2025
Figure 19. Drugs for Spinal Muscular Atrophy (SMA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
Figure 22. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
Figure 23. United States Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
Figure 26. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
Figure 27. Germany Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021–2032)
Figure 34. China Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
Figure 42. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Type (2021–2032)
Figure 53. Global Revenue Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Type (2021–2032)
Figure 54. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Application (2021–2032)
Figure 56. Global Revenue Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Application (2021–2032)
Figure 57. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2021–2032)
Figure 58. Drugs for Spinal Muscular Atrophy (SMA) Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation by Manufacturers in 2025
Table 4. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Drugs for Spinal Muscular Atrophy (SMA), Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Types and Applications
Table 12. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Drugs for Spinal Muscular Atrophy (SMA) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Drugs for Spinal Muscular Atrophy (SMA) Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2021–2026
Table 18. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021–2026)
Table 19. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2027–2032
Table 20. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2027–2032)
Table 21. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2021–2026
Table 22. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021–2026)
Table 23. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2027–2032
Table 24. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2027–2032)
Table 25. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
Table 27. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
Table 28. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
Table 29. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
Table 32. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
Table 33. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
Table 42. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
Table 43. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (US$ Million), 2027–2032
Table 50. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Type (2021–2026)
Table 51. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Type (2027–2032)
Table 52. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2021–2026)
Table 53. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2027–2032)
Table 54. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2021–2026)
Table 57. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2027–2032)
Table 58. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2021–2026)
Table 59. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2027–2032)
Table 60. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Application (2021–2026)
Table 61. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Application (2027–2032)
Table 62. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2021–2026)
Table 63. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2027–2032)
Table 64. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2021–2026)
Table 67. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2027–2032)
Table 68. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2021–2026)
Table 69. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2027–2032)
Table 70. Novartis Company Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Novartis Drugs for Spinal Muscular Atrophy (SMA) Product
Table 74. Novartis Recent Developments/Updates
Table 75. Genentech Company Information
Table 76. Genentech Description and Business Overview
Table 77. Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Genentech Drugs for Spinal Muscular Atrophy (SMA) Product
Table 79. Genentech Recent Developments/Updates
Table 80. Biogen Company Information
Table 81. Biogen Description and Business Overview
Table 82. Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Biogen Drugs for Spinal Muscular Atrophy (SMA) Product
Table 84. Biogen Recent Developments/Updates
Table 85. Ionis Pharmaceuticals Company Information
Table 86. Ionis Pharmaceuticals Description and Business Overview
Table 87. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product
Table 89. Ionis Pharmaceuticals Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Drugs for Spinal Muscular Atrophy (SMA) Distributors List
Table 93. Drugs for Spinal Muscular Atrophy (SMA) Customers List
Table 94. Drugs for Spinal Muscular Atrophy (SMA) Market Trends
Table 95. Drugs for Spinal Muscular Atrophy (SMA) Market Drivers
Table 96. Drugs for Spinal Muscular Atrophy (SMA) Market Challenges
Table 97. Drugs for Spinal Muscular Atrophy (SMA) Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Product Picture of Drugs for Spinal Muscular Atrophy (SMA)
Figure 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Type: 2025 & 2032
Figure 4. Oral Drugs Product Picture
Figure 5. Injections Product Picture
Figure 6. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Application: 2025 & 2032
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Other
Figure 11. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (US$ Million), 2021–2032
Figure 13. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), 2021–2032
Figure 14. Global Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit), 2021–2032
Figure 15. Drugs for Spinal Muscular Atrophy (SMA) Report Years Considered
Figure 16. Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Manufacturers in 2025
Figure 17. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Drugs for Spinal Muscular Atrophy (SMA) Players: Market Share by Revenue in Drugs for Spinal Muscular Atrophy (SMA) in 2025
Figure 19. Drugs for Spinal Muscular Atrophy (SMA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
Figure 22. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
Figure 23. United States Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
Figure 26. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
Figure 27. Germany Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2021–2032)
Figure 34. China Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
Figure 42. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Type (2021–2032)
Figure 53. Global Revenue Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Type (2021–2032)
Figure 54. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Application (2021–2032)
Figure 56. Global Revenue Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Application (2021–2032)
Figure 57. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2021–2032)
Figure 58. Drugs for Spinal Muscular Atrophy (SMA) Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232